Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Non Operating Income (2016 - 2025)

Amicus Therapeutics' Non Operating Income history spans 15 years, with the latest figure at -$2.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 188.14% year-over-year to -$2.2 million, compared with a TTM value of $10.2 million through Dec 2025, up 208.51%, and an annual FY2025 reading of $10.2 million, up 208.51% over the prior year.
  • Non Operating Income for Q4 2025 was -$2.2 million at Amicus Therapeutics, down from $10.9 million in the prior quarter.
  • The five-year high for Non Operating Income was $13.6 million in Q3 2022, with the low at -$18.6 million in Q4 2022.
  • Average Non Operating Income over 5 years is -$690400.0, with a median of $31000.0 recorded in 2021.
  • Biggest YoY gain for Non Operating Income was 5652.74% in 2022; the steepest drop was 10730.23% in 2022.
  • Tracing FOLD's Non Operating Income over 5 years: stood at -$172000.0 in 2021, then tumbled by 10730.23% to -$18.6 million in 2022, then skyrocketed by 84.54% to -$2.9 million in 2023, then skyrocketed by 187.01% to $2.5 million in 2024, then tumbled by 188.14% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Non Operating Income are -$2.2 million (Q4 2025), $10.9 million (Q3 2025), and $1.0 million (Q2 2025).